Today: 23 January 2026
Subscribe
Browse Category

NASDAQ:TEAM News 17 January 2026 - 23 January 2026

Atlassian stock pops in premarket — what traders are watching next for TEAM

Atlassian stock pops in premarket — what traders are watching next for TEAM

NEW YORK, January 23, 2026, 05:14 EST — Premarket Atlassian shares ticked up roughly 0.5% in early trading Friday, hovering near $129, following a 4.9% gain that pushed them to $128.44 at Thursday’s close. (StockAnalysis) The bounce is significant since Atlassian has been volatile in January, with investors debating two key issues: the pricing power of its self-managed products and…
23 January 2026
·····
Atlassian stock price slides 8% on Citi target cut and insider sales as earnings loom

Atlassian stock price slides 8% on Citi target cut and insider sales as earnings loom

New York, Jan 17, 2026, 05:19 (EST) — The market has closed. Atlassian Corp (TEAM.O) shares fell 7.7% Friday, closing at $118.55 after trading between $129.46 and $118.08 during the session. The stock finished $9.90 below Thursday’s closing price. (Yahoo Finance) The decline is significant as it comes just before a crucial period for U.S. software stocks, when analysts and…
17 January 2026
·····

Stock Market Today

  • Oric Pharmaceuticals Shares Poised for 74% Upside as Biotech Innovation Draws Investor Attention
    January 23, 2026, 8:13 AM EST. Oric Pharmaceuticals (NASDAQ: ORIC) is gaining investor interest with a potential 74% upside from its current $12.05 share price, backed by partnerships with Pfizer, Bayer, and Johnson & Johnson. The clinical-stage biotech focuses on therapies addressing cancer treatment resistance, advancing candidates like ORIC-114 and ORIC-944 through early-stage trials. Despite a $1.17 billion market cap, Oric reports a negative EPS of -1.71 and free cash flow of -$70.7 million, reflecting typical high-risk biotech dynamics. With no dividends and a neutral RSI, stock momentum shows cautious optimism. Analysts rate ORIC with 14 buys and project a $21 average target price, suggesting substantial growth for investors able to tolerate the sector's inherent uncertainties.
Go toTop